tration, and occurrence of symptomatic hypotension.
Results. The study included 33 patients. Mean PCWP was reduced by 31.1% with the addition of nesiritide to previous therapy (p < 0.0001). Significant improvements in other hemodynamic variables, including MPAP (15.6% reduction) and CI (13.0% increase), were also observed. MAP was reduced significantly (by 15.2%), but SCr concentration did not change. There were five episodes of symptomatic hypotension. All patients exhibited relief of dyspnea symptoms. Conclusion. The addition of nesiritide to standard therapy and positive inotropic agents improved hemodynamic measures and clinical symptoms in patients with endstage heart failure and secondary pulmonary hypertension.
Index terms: Cardiac drugs; Combined therapy; Heart failure; Hypertension; Nesiritide; Toxicity Am J Health-Syst Pharm. 2005; 62:606-9 H eart failure is a serious public health problem in the United States. Since the early 1980s, the mortality rate for patients with heart failure has increased by nearly 150%. Over 200,000 people die annually of heart failure, and many patients who are diagnosed with the disease before the age of 65 years die within 8 years.
1 Life expectancy is even lower for those with advanced (New York Heart Association [NYHA] functional class IV) heart failure. Often, heart transplantation represents the only treatment option for these patients.
Preoperative pulmonary hypertension (PH) has been found to significantly increase the mortality rate in the 30 days after heart transplantation. 2 Therefore, end-stage heart-failure patients whose PH is reversible may be eligible for cardiac transplantation, while those with irreversible PH may not be. 3 PH is manifested as increased pressure within the pulmonary arteries. The increased arterial pressure is due to poor cardiac output, which causes increased backflow of blood into the pulmonary circulation and a reactive increase in resistance within the pulmonary arterial system. The latter is likely stimulated by neurohormonal modulators that are elevated during heart failure. 4 Brain natriuretic peptide (BNP) is a neurohormonal modulator that is elevated in patients with heart fail-Am J Health-Syst Pharm-Vol 62 Mar 15, 2005 ure. 5 BNP has both vasodilatory and natriuretic properties in these patients. Also, BNP reduced pulmonary artery pressure in an animal model of PH, suggesting that exogenous BNP could play a role in the treatment of PH associated with heart failure. 6 Nesiritide (synthetic human Btype natriuretic peptide) is a recombinant form of BNP and is the most recently approved agent for the acute management of decompensated heart failure. Nesiritide improves hemodynamic variables, such as pulmonary capillary wedge pressure (PCWP), in patients hospitalized for heart failure management. [7] [8] [9] However, clinical studies of nesiritide have not explored the use of the agent in patients with end-stage heart failure, who may be eligible for cardiac transplantation. Whether nesiritide produces incremental benefits when added to standard heart-failure therapy and positive inotropic agents remains unclear.
Our article describes a retrospective assessment of the impact of adding nesiritide to standard therapy and positive inotropic agents in patients with end-stage heart failure and PH.
Methods
Our study was performed at a 903-bed tertiary care teaching hospital and was reviewed and approved by the institutional review board. Informed consent was not required. Patients who received nesiritide and either milrinone or dobutamine or both between November 2001 and the end of December 2002 were initially identified through the pharmacy database. Patients were further identified from the Corporate Data Store, an administrative and billing database, for diagnosis of heart failure and central venous catheter placement.
Secondary PH was defined as pulmonary artery systolic pressure higher than 30 mm Hg or mean pulmonary artery pressure higher than 20 mm Hg secondary to a cardiac disorder. Patients included in the analysis were 18 years of age or older, were admitted to the hospital with PH secondary to end-stage heart failure (NYHA functional class IV), had received a Swan-Ganz pulmonary artery catheter, had received nesiritide because of inadequate hemodynamic response to previous therapy (PCWP, >18 mm Hg), and had shown minimal symptomatic benefit from standard therapy for chronic heart failure (angiotensinconverting-enzyme inhibitors and low-dose β-blockers), continuous infusions of loop diuretics, and positive inotropic agents (milrinone or dobutamine or both).
Nesiritide was administered as a bolus i.v. injection (2 µg/kg), followed by a continuous i.v. infusion (0.01 µg/kg/min). The duration of therapy was based on the patient's hemodynamic and clinical responses.
Demographic and clinical data were collected from the patients' medical records. The primary endpoint was change in PCWP. Changes in mean pulmonary artery pressure (MPAP), cardiac index (CI), and mean arterial pressure (MAP) were secondary hemodynamic endpoints. Hemodynamic measurements, obtained immediately before and at the end of nesiritide administration, were collected through chart review. Hemodynamic data collected included PCWP, MPAP, CI, and MAP. Serum creatinine (SCr) concentration was also studied. All hemodynamic variables were measured with a Swan-Ganz pulmonary artery catheter (Edwards Lifesciences LLC, Irvine, CA). Secondary clinical endpoints were symptomatic hypotension, need for a left ventricular assist device (LVAD), transplant status, and renal function.
Descriptive statistics were used to report patient characteristics and clinical endpoints. Continuous variables were reported as mean ± S.D. PCWP, MPAP, CI, MAP, and SCr concentration, measured before and at the end of nesiritide infusion, were compared by using the paired t test. On the basis of previous literature reporting a mean ± S.D. nesiritideassociated reduction in PCWP of 6.0 ± 6.5 mm Hg, 7 and assuming α of 0.05 and β of 0.8, we estimated that a sample of 12 patients would be necessary to detect a change in PCWP. However, as a conservative strategy, we decided to evaluate the medical records of 40 consecutive patients with NYHA functional class IV heart failure. Data analysis was performed with the SPSS statistical software program (version 10.0, SPSS, Inc., Chicago, IL). A p value of less than 0.05 was considered significant.
Results
Of the 40 patients evaluated, 7 were excluded from the analysis because they did not have a pulmonary artery catheter in place at the time of nesiritide infusion. Thirty-three patients were included in the final analysis. The mean ± S.D. duration of nesiritide therapy was 4.1 ± 4.5 days (range, 1-21 days), with 42% of patients requiring ≤48 hours of nesiritide therapy. The mean ± S.D. age of patients was 43.6 ± 11.1 years, and 64% of them were men (Table 1) . Mean ± S.D. left ventricular ejection fraction was 17.2% ± 12.5%.
Mean PCWP was reduced by 31.1% (p < 0.0001) with the addition of nesiritide to standard heart-failure therapy, continuous infusions of loop diuretics, and positive inotropic therapy ( Table 2) . We also observed significant improvements in other hemodynamic variables with the addition of nesiritide, including MPAP (15.6% reduction) and CI (13.0% increase). All patients exhibited relief of dyspnea symptoms, as documented by physical examination.
MAP was reduced significantly by 15.2%. SCr levels did not change significantly. Five patients had distinct episodes of symptomatic hypotension, necessitating the postponement or discontinuation of nesiritide ther- Twenty-five (75.8%) of the patients either underwent heart transplantation or were placed on the waiting list for a heart transplant. Of the remaining patients, two were still being evaluated for eligibility for a heart transplant at the end of the study, and six had been deemed ineligible. Medication noncompliance was the main reason for removal from the transplant list. LVADs were implanted in 15 (45.5%) of patients as bridge therapy to transplantation; only 1 patient had emergency LVAD placement.
Discussion
In this retrospective study, we observed significant improvements in PCWP, MPAP, and CI when nesiritide was added to standard and inotropic therapies in heart-failure patients with secondary PH who were undergoing evaluation for a heart transplant.
Few studies of the use of nesiritide in this patient population are available. [10] [11] [12] One article described the safety and efficacy of the combination of nesiritide and positive inotropic therapy in a case series. 10 Four heart-transplant candidates were treated with nesiritide for 11-35 days, in addition to milrinone or dobutamine and i.v. diuretics. These patients were able to maintain adequate PCWP, MPAP, and clinical stability while awaiting transplantation.
Our findings are in general concordance with the Vasodilation in the Management of Acute CHF (VMAC) trial, in which patients with less severe heart failure (decompensated, but not end stage) were treated with nesiritide. 7 We saw similar, although more pronounced, improvements in PCWP and CI among our patients (a 21% reduction and a 4.5% increase, respectively) compared with those in the VMAC study.
Our patients had greater hemodynamic improvement than the VMAC study patients, even though nesiritide was added to inotropic therapy for all our patients, while only 30% of the VMAC trial patients were concomitantly treated with inotropes. The larger effect in our patients was likely due to their greater severity of illness. The greater severity of illness in our patients probably also accounted for the longer mean duration of therapy (four days) than in the VMAC trial (one day) and for the higher rate of symptomatic hypotension necessitating postponement of therapy in our study (there was only one case of severe hypotension in the VMAC trial).
Milrinone, a cyclic AMP phosphodiesterase inhibitor, has positive inotropic and vasodilatory activity, resulting in improved diastolic function and myocardial contractility. Dobutamine, a β 1 -adrenergicreceptor agonist, increases myocardial contractility and stroke volume, leading to increased cardiac output. Dobutamine also exhibits secondary hemodynamic effects, including decreases in systemic vascular resistance (afterload) and ventricular filling pressure (preload). Nesiritide shares its vasodilatory effects with the positive inotropic agents, but unlike the inotropes, nesiritide also has natriuretic and diuretic properties. Therefore, it is not unexpected that the addition of nesiritide to positive inotropic therapy would provide additive benefits.
The retrospective design of our study is an inherent limitation. Certain clinical information, such as patients' symptoms, was not always adequately documented in the medical record. However, we do know that all patients were similar in terms of hemodynamic presentation and poor left ventricular systolic function, and all were being evaluated for heart transplantation. Therefore, it is likely that these patients were homogeneous from a cardiac clinical stand- 29.6 ± 6.4 43.6 ± 8.9
2.3 ± 0.7 81.8 ± 11.0 1.5 ± 0.6 point. Although a standard dosage of nesiritide was used for all patients, reports have described further improvements with upward adjustment of the dosage. 8 Also, the dosage of the inotropic agent was not prospectively controlled and could have differed among patients. Although inotropic therapy was documented, the lack of dosage-adjustment data is another potential study limitation. Finally, the small sample and the use of patients from a single center are possible limitations. Given the retrospective design of our study, our findings should be considered "hypothesis generating" and suggest a need for large prospective studies to assess the potential benefits of nesiritide as an adjunctive therapy in patients with end-stage heart failure.
Conclusion
The addition of nesiritide to standard therapy and positive inotropic agents improved hemodynamic measures and clinical symptoms in patients with end-stage heart failure and secondary PH.
